GlassScriptPhysician profile
Qun Xu
NPI 1689837684
$8,174.58
in general payments reported to CMS, 2019-2025
31 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $353 · 2022: $1,641 · 2023: $2,281 · 2024: $2,289 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,959 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,959.27 |
| Education | $220.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,822.95 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,303.87 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $875.11 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $569.40 | 2021-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $518.60 | 2021-2025 | Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $356.86 | 2023-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $252.65 | 2022-2025 | Dupixent |
| Celgene Corporation | $242.12 | 2022-2024 | Zeposia |
| Pfizer INC. | $233.07 | 2021-2025 | |
| Ardelyx, INC. | $205.31 | 2022-2024 | Ibsrela |
| Lilly USA, LLC | $197.69 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $183.09 | 2022-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $163.99 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $159.34 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $158.82 | 2022-2024 | Linzess |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $141.08 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $126.47 | 2022-2024 | Rebyota, Clenpiq |
| Aimmune Therapeutics, INC. | $125.81 | 2024-2025 | Vowst, Zenpep |
| Nestle Healthcare Nutrition INC. | $95.82 | 2022-2023 | |
| Celltrion USA INC. | $80.88 | 2023-2025 | Vegzelma, Yuflyma |
| Genzyme Corporation | $72.35 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $47.56 | 2025 | Iqirvo |
| Amgen INC. | $45.45 | 2023 | Amjevita, Avsola |
| Madrigal Pharmaceuticals | $43.21 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $30.19 | 2025 | The Cologuard Plus Collection Kit |
| Daiichi Sankyo INC. | $28.89 | 2022 | |
| Mallinckrodt Hospital Products INC. | $21.81 | 2023 | Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $20.09 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.79 | 2024 | Simlandi |
| Organon LLC | $18.33 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.98 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qun Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.